Vaneltix Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Private
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://vaneltix.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Vaneltix Pharma, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06394830
- Locations
- 🇺🇸
Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Valley Urology, Inc., Fresno, California, United States
🇺🇸Prestige Medical Group, Tustin, California, United States
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
Phase 2
Recruiting
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Vaneltix Pharma, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05737121
- Locations
- 🇺🇸
The Clark Center for Urogynecology, Newport Beach, California, United States
🇺🇸The Wake Forest Institute of Regenerative Medicine, Winston-Salem, North Carolina, United States
🇺🇸IC Study LLC, Escondido, California, United States
News
No news found